Investor group backs oncology support app developed by German health company Fosanis. The capital raised is intended to drive Mika’s international expansion beyond its core German market
Please subscribe or log in
This article is available to Impact Investor members.
Get full access to the pan-European news platform for professionals in impact investing and sustainable finance. We deliver independent, high-quality journalism that follows the flow of European capital — where it goes, what it achieves, and who is driving the change.
What your membership includes
- Unlimited digital access to all Impact Investor reporting and archives
- Exclusive member newsletters, including Impact Watch, Impact Intelligence, and The Impact Conversation
- Free access to all Impact Investor events *
Join us now!
€99 for your first year
Full access. Cancel anytime.
* Event access for Asset Managers and Impact VCs above €100m AUM is via sponsorship and not included in standard subscriptions.